Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
Medtronic (MDT), Abbott Laboratories (ABT), and Johnson & Johnson (JNJ) have long dividend growth streaks. MDT yields 2.95%, ABT 2.46%, and JNJ 2.0%. MDT's Q1 revenue rose 13.7%, while ABT and JNJ are restructuring. All pay out ~50% of earnings, with strong free cash flow.
How this was made
The 30-second read
Why it matters
Provides fresh cash‑flow data and guidance updates that may shift income‑investor allocations toward MDT and JNJ, while ABT faces mixed signals from its recent acquisition.
Market read
Income‑focused investors may re‑balance toward the highlighted medtech dividend leaders, especially MDT after its strong cash‑flow surprise.
What to watch
Potential regulatory pressures on medical‑device pricing and the pending MiniMed spin‑off for MDT could introduce execution risk.
Background
The article compares three long‑standing dividend payers in the medical‑device space, focusing on yield, cash flow, and payout sustainability.
Ticker impact
MDT reported FY2026 free cash flow of $5.43B and Q1 FY2027 free cash flow of $1.29B, up 120.9% YoY, and raised FY2027 EPS guidance to $5.94‑$6.00.
likely modest upside as dividend‑seeking buyers add to the stock
Free cash flow surge and higher EPS guidance reduce payout risk, making the 2.95% yield more appealing.
ABT posted a 410‑quarter dividend streak, 54‑year increase record, and disclosed a $21B Exact Sciences acquisition that raised interest expense and diluted EPS.
potential slight downside from higher debt, offset by dividend appeal
Higher interest expense and lower GAAP coverage raise risk, while the 2.46% yield remains attractive.
JNJ announced its 64th consecutive dividend increase, raising the quarterly payout 3.1% to $1.34 and maintaining a 2% yield.
steady or modestly bullish as investors value the AAA credit rating and dividend growth
Robust MedTech cash flow and low volatility make the dividend increase a confidence boost.
Market effects
Highlights the resilience of the medical‑device and health‑care dividend space, potentially drawing capital from broader dividend‑seeking funds.
U.S. health‑care sector may see modest inflows as income investors rotate into high‑yield medtech stocks.
Reinforces the attractiveness of stable dividend payers worldwide, supporting global dividend‑focused strategies.
Counterpoint
Rising payout ratios (near 50% of earnings) could become unsustainable if free cash flow slows, making the stocks vulnerable to a pull‑back.
Key entities
- companyMedtronic
Medical device maker with a 49‑year dividend streak.
- companyAbbott Laboratories
Dividend King with a 54‑year streak, recent acquisition impact.
- companyJohnson & Johnson
Longest streak at 64 years, strong MedTech cash flow.
